AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
E1B Deleted Adenovirus Infection Inhibits Tumor Growth In Vivo.
2001 MAY 17 - (NewsRx Network) -- by Deborah W. Heinrich, PhD, staff medical writer Researchers at Beatson Laboratory in Scotland demonstrated that infection with an E1B 55kDa deleted adenovirus (ONYX-0 15) inhibited tumor growth in vivo.
I. Ganly and colleagues noted that the ONYX-015 adenovirus induced lysis of cells with p53 mutations. In this study, they used ONYX-015 to infect human ovarian tumor cell lines with known p53 mutations and chemoresistance and reported their results in Gene Therapy.
The parent cell line, A2780, is chemosensitive to cisplatin and expresses wild-type p53. The mutant p53 derivative, A2780/cp70 is cisplatin resistant. Ganly and coworkers discovered that infection with ONYX-015 resulted in A2780/cp70 cytopathology in vitro and inhibition of tumor growth in vivo. Cytopathology and tumor inhibition were not observed after ONYX-015 infection of the A2780 parent cells.
Interestingly, this research group reported that when the chemosensitive A2780 was infected with ONYX-015, apoptosis increased and clonogenic survival decreased. They found, further, that ONYX-015 infection increased expression of proapoptotic BAX and decreased expression of antiapoptotic BCLXL ("Replication and cytolysis of an EIB-attenuated adenovirus in ...
- We Now Have Many Areas Where We Have a Good Understanding of the Science of...
- Press release article from: Business Wire January 23, 2006 700+ words
...cancer and therefore where to focus to intervene to disrupt tumor growth. The report explores three of the more interesting avenues...GlaxoSmithKline Imclone Johnson & Johnson Merck Millenium Novartis Onyx Pharmaceuticals OSI Pharmaceutical Oxigene Pfizer Regeneron...
- Onyx's cancer drug gets boost.
- News wire article from: Contra Costa Times (Walnut Creek, CA) March 22, 2005 700+ words
...The prospect of approval had Onyx Chief Executive Officer Hollings...patients die each year. However, Onyx and its partner Bayer Pharmaceuticals...whether the drug also slows tumor growth for other difficult-to-treat...melanoma. Under Renton's watch, Onyx has fought its way through a...
- Onyx Provides Update of Development Programs; Meets Key Manufacturing Milestone.
- Press release article from: PR Newswire November 14, 2002 700+ words
...milestone-based loan payment to Onyx. Multiple Phase I clinical...commencement of Phase III studies, Onyx will receive $15 million in...blocking this pathway may inhibit tumor growth. Mutations in the ras gene...Society. Development Update on ONYX-015 The clinical progress...
- BAY 43-9006, ONYX-015 moving forward.
- Newspaper article from: Cancer Weekly December 31, 2002 700+ words
...milestone-based loan payment to Onyx. Multiple phase I clinical...commencement of phase III studies, Onyx will receive $15 million in...blocking this pathway may inhibit tumor growth. Mutations in the ras gene...Society. The clinical progress of ONYX-015 has been limited to date...
- ONYX-015 Clinical Trial Data Presented at ASCO Meeting.
- Press release article from: Business Wire May 19, 1997 700+ words
...received repeat treatment of ONYX-015. Ten patients experienced...We were pleased to find ONYX-015 safe and free of any major...effect of injection on solid tumor growth was a secondary objective of...also studied the ability of ONYX-015 to replicate in solid...
- Onyx Updates Phase I Data for BAY 43-9006 at 2002 EORTC-NCI-AACR Meeting in...
- Press release article from: PR Newswire November 20, 2002 700+ words
...developed in a collaboration between Onyx and Bayer. The updated data...Leonard E. Post, Ph.D., Onyx senior vice president, research...blocking this pathway may inhibit tumor growth. Mutations in the ras gene...development collaboration between Onyx and Bayer results in Onyx ...
- ONYX Begins Testing of Adenovirus in Pancreatic Cancer.
- Press release article from: Business Wire March 3, 1997 700+ words
...cancers. In this new study of ONYX-015, the product is administered...intra-tumoral injection of ONYX-015. The Phase I study is...any effects of the virus on tumor growth. The principal investigator...and blocks its function. The ONYX-015 adenovirus is modified...
- Onyx begins human testing of adenovirus in ovarian cancer.
- Press release article from: Business Wire April 3, 1997 700+ words
...cases. In this new study of ONYX-015 in ovarian cancer, the...existing clinical studies of ONYX-015, the ovarian trial is...any effects of the virus on tumor growth. The principal investigator...investigators for the Phase I trial of ONYX-015 in head and neck tumors...
- UPDATE 2-Onyx Pharmaceuticals falls 27% on drug trial results.
- News wire article from: The America's Intelligence Wire October 25, 2004 700+ words
...effective in shrinking tumors. Onyx management said that those results...earlier studies. Bayer and Onyx are in the process of beginning...for the drug that will measure tumor growth, tumor shrinkage and patient...how the drug will compete." Onyx management said the company...
- UPDATE 1-Onyx Pharmaceuticals falls 27% on drug trial results.
- News wire article from: The America's Intelligence Wire October 25, 2004 700+ words
...effective in shrinking tumors. Onyx management said that those results...in early studies. Bayer and Onyx are in the process of beginning...for the drug that will measure tumor growth, tumor shrinkage and patient...Food and Drug Administration. Onyx management said that the company...
Source: HighBeam Research, E1B Deleted Adenovirus Infection Inhibits Tumor Growth In Vivo.